Ann: Update on BLA for Graft Versus Host Disease, page-211

First 211 Last

Share
Profile

Follow
gnewton87

181 Posts.

8

02/10/20

10:18

Post #: 47801027
Share

Originally posted by angelus512: ↑

Well as promised I got out at market auction at 3.00. Unfortunate as it jumped up to 3.15 but none the less we never know which way things will go. Most unfortunate what has occurred today and I must say there should be more than enough justified finger pointing at the FDA at this point given the ODAC committee vote.

I think this will end up seeing approval one day but thats beside the point. This was supposed to be the "easy win" approval which now cast doubts on everything else. With no positive news incoming (if ARDS is not) then this stock will without doubt drift back to its historical $1.00 zone valuation in my view as the shorters will now be all of this and rightfully so.

Fortunately for me I took a minor loss at auction as my ownership prices were lower. Aside from the finger pointing at the FDA there is at list one finger that should be pointed at MSB.
The FDA in my view has pushed back on this and consistently made mention of one thing that they *DID NOT* like (no matter how stupid it was). They wanted random placebo controlled trials and they said it again and again.

Yes it was sick and depraved to do that to kids but the FDA clearly made a point for some time now to MSB that they had requested this and MSB ignored them. Now they have to go back and do what the FDA asked them to do at the beginning. In hindsight that is MSB's fault, irrespective of whether or not having random placebo on kids is gross.

Aside from all that though. I must say its unbelievable to me how the FDA can reject something that is safe and has no adverse side effects when nothing else is there for treatment. This is the only option. ODAC also backed us up and yet the FDA is all "no thanks we know better" whilst they approve dangerous drugs with huge side effects like Jakafi.

Thats really sick tbh. But we all have to make the calls as best for us. I didn't want to sell but seeing what was supposed to be one of the most guaranteed easy wins for MSB and see us fail. I'm not going to be holding the bag down to $1.00 again like I was last time (only to see it go up again sure) but I am not hanging on for that wild ride again.

I'll consider buying back when it has bottomed out fully again possibly. Or I'll buy in if they actually get approved for something.

Expand

Yeah nice try but this is going nowhere near $1 again unless there is a market crash. All the best to you though on that one

MSB Price at posting: $3.22 Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

TMG

Trigg shares up 16% on Wild Cattle Creek antimony acquisition

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HAS

Hastings progressing Yangibana to production with lower costs

There are more pages in this discussion • 345 more messages in this thread...

First 211 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.15		Change 0.025(2.22%)		Mkt cap ! $1.313B

Open	High	Low	Value	Volume
$1.13	$1.18	$1.13	$3.219M	2.801M

Buyers (Bids)

No.	Vol.	Price($)
25	50229	$1.15

Sellers (Offers)

Price($)	Vol.	No.
$1.16	65505	34

View Market Depth

No.	Vol.	Price($)
21	48705	1.150
17	89695	1.145
11	46311	1.140
12	113080	1.135
10	391643	1.130

Price($)	Vol.	No.
1.155	60811	27
1.160	61692	11
1.165	123582	14
1.170	156907	32
1.175	92879	11

Last trade - 14.15pm 30/09/2024 (20 minute delay)

MSB (ASX) Chart

Ann: Update on BLA for Graft Versus Host Disease, page-211

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Trigg shares up 16% on Wild Cattle Creek antimony acquisition

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Hastings progressing Yangibana to production with lower costs

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Update on BLA for Graft Versus Host Disease, page-211

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Trigg shares up 16% on Wild Cattle Creek antimony acquisition

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Hastings progressing Yangibana to production with lower costs

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News